- conflicts or gaps
- [[{"field": {"value": "company_slug", "source_urls": ["https://www.ycombinator.com/companies/asher-bio", "https://yc-oss.github.io/api/batches/summer-2019/asher-bio.json"]}, "issue": {"value": "Internal/database slug asher_bio (underscore) vs YC public slug asher-bio (hyphen).", "source_urls": ["https://www.ycombinator.com/companies/asher-bio", "https://yc-oss.github.io/api/batches/summer-2019/asher-bio.json"]}}, {"field": {"value": "identity.headquarters", "source_urls": ["https://www.ycombinator.com/companies/asher-bio", "https://yc-oss.github.io/api/batches/summer-2019/asher-bio.json", "https://asherbio.com/2026/05/21/asher-biotherapeutics-announces-two-presentations-at-the-asco-2026-annual-meeting-highlighting-clinical-progress-across-its-cd8-targeted-cytokine-pipeline/"]}, "issue": {"value": "Location varies: YC lists San Francisco and San Carlos; company press releases and website use South San Francisco; May 2026 ASCO press release dateline uses San Mateo, Calif.", "source_urls": ["https://www.ycombinator.com/companies/asher-bio", "https://yc-oss.github.io/api/batches/summer-2019/asher-bio.json", "https://asherbio.com/2024/04/16/asher-bio-closes-55-million-series-c-financing-to-advance-lead-program-into-phase-1b-clinical-trials/", "https://asherbio.com/2026/05/21/asher-biotherapeutics-announces-two-presentations-at-the-asco-2026-annual-meeting-highlighting-clinical-progress-across-its-cd8-targeted-cytokine-pipeline/"]}}, {"field": {"value": "founders", "source_urls": ["https://www.ycombinator.com/companies/asher-bio", "https://www.businesswire.com/news/home/20210323005426/en/Asher-Bio-Launches-with-55-Million-Series-A-Financing-Led-by-Third-Rock-Ventures-to-Discover-and-Develop-Highly-Specific-Immunotherapies-Using-a-Novel-Technology-Platform"]}, "issue": {"value": "YC lists two operational founders (Ivana Djuretic, Andy Yeung); Series A press release and 2021 company profile also name academic co-founders Robert Schreiber and Ton Schumacher.", "source_urls": ["https://www.ycombinator.com/companies/asher-bio", "https://www.businesswire.com/news/home/20210323005426/en/Asher-Bio-Launches-with-55-Million-Series-A-Financing-Led-by-Third-Rock-Ventures-to-Discover-and-Develop-Highly-Specific-Immunotherapies-Using-a-Novel-Technology-Platform", "https://asherbio.com/wp-content/uploads/2021/05/032921BC_ECP_AsherBio.pdf"]}}, {"field": {"value": "leadership.ceo", "source_urls": ["https://www.businesswire.com/news/home/20210323005426/en/Asher-Bio-Launches-with-55-Million-Series-A-Financing-Led-by-Third-Rock-Ventures-to-Discover-and-Develop-Highly-Specific-Immunotherapies-Using-a-Novel-Technology-Platform", "https://asherbio.com/about-us/", "https://www.linkedin.com/in/crgibbs"]}, "issue": {"value": "Craig Gibbs was CEO at Series A launch (March 2021); LinkedIn lists Gibbs as CEO Sep 2020–Sep 2025; current company about page lists co-founder Ivana Djuretic as CEO; Ivana LinkedIn headline still shows CSO role.", "source_urls": ["https://www.businesswire.com/news/home/20210323005426/en/Asher-Bio-Launches-with-55-Million-Series-A-Financing-Led-by-Third-Rock-Ventures-to-Discover-and-Develop-Highly-Specific-Immunotherapies-Using-a-Novel-Technology-Platform", "https://asherbio.com/about-us/", "https://www.linkedin.com/in/crgibbs", "https://www.linkedin.com/in/ivana-djuretic-730a1517/"]}}, {"field": {"value": "employees.snapshots", "source_urls": ["https://www.ycombinator.com/companies/asher-bio", "https://tracxn.com/d/companies/asherbiotherapeutics/__tUfwQphgotV2QUNLcSLWsnQ8rklOetceDiIDV2bq7-I", "https://www.linkedin.com/company/asher-biotherapeutics"]}, "issue": {"value": "Headcount varies widely: YC team_size 3 (2019), company profile 23 (May 2021), Tracxn 17 (Mar 2026), LinkedIn 18 (2026); LinkedIn also reports ~46% YoY decline.", "source_urls": ["https://www.ycombinator.com/companies/asher-bio", "https://asherbio.com/wp-content/uploads/2021/05/032921BC_ECP_AsherBio.pdf", "https://tracxn.com/d/companies/asherbiotherapeutics/__tUfwQphgotV2QUNLcSLWsnQ8rklOetceDiIDV2bq7-I", "https://www.linkedin.com/company/asher-biotherapeutics"]}}, {"field": {"value": "funding.total_raised_usd", "source_urls": ["https://www.cbinsights.com/company/asher-bio/financials", "https://tracxn.com/d/companies/asherbiotherapeutics/__tUfwQphgotV2QUNLcSLWsnQ8rklOetceDiIDV2bq7-I/funding-and-investors"]}, "issue": {"value": "CB Insights reports $218.64M over 6 rounds; Tracxn reports $218M over 4 rounds; announced Series A/B/C sum to $218M excluding undisclosed seed; seed amount ($150K) only found in secondary aggregator Startup Intros.", "source_urls": ["https://www.cbinsights.com/company/asher-bio/financials", "https://tracxn.com/d/companies/asherbiotherapeutics/__tUfwQphgotV2QUNLcSLWsnQ8rklOetceDiIDV2bq7-I/funding-and-investors", "https://startupintros.com/news/2019-08-01-asher-bio-seed", "https://asherbio.com/2021/03/23/asher-bio-launches-with-55-million-series-a-financing-led-by-third-rock-ventures-to-discover-and-develop-highly-specific-immunotherapies-using-a-novel-technology-platform/"]}}, {"field": {"value": "funding.rounds[Series C].announced_at", "source_urls": ["https://asherbio.com/2024/04/16/asher-bio-closes-55-million-series-c-financing-to-advance-lead-program-into-phase-1b-clinical-trials/", "https://tracxn.com/d/companies/asherbiotherapeutics/__tUfwQphgotV2QUNLcSLWsnQ8rklOetceDiIDV2bq7-I/funding-and-investors"]}, "issue": {"value": "Company press release dated April 16, 2024; Tracxn lists April 3, 2024 for Series C.", "source_urls": ["https://asherbio.com/2024/04/16/asher-bio-closes-55-million-series-c-financing-to-advance-lead-program-into-phase-1b-clinical-trials/", "https://tracxn.com/d/companies/asherbiotherapeutics/__tUfwQphgotV2QUNLcSLWsnQ8rklOetceDiIDV2bq7-I/funding-and-investors"]}}, {"field": {"value": "funding.valuation_usd", "source_urls": ["https://forgeglobal.com/asher-biotherapeutics_ipo/", "https://www.cbinsights.com/company/asher-bio/financials"]}, "issue": {"value": "No primary-source valuati...
- source urls
- ["https://asherbio.com/2021/03/23/asher-bio-launches-with-55-million-series-a-financing-led-by-third-rock-ventures-to-discover-and-develop-highly-specific-immunotherapies-using-a-novel-technology-platform/", "https://asherbio.com/2021/09/01/asher-bio-closes-108-million-series-b-financing/", "https://asherbio.com/2024/04/16/asher-bio-closes-55-million-series-c-financing-to-advance-lead-program-into-phase-1b-clinical-trials/", "https://asherbio.com/2026/05/21/asher-biotherapeutics-announces-two-presentations-at-the-asco-2026-annual-meeting-highlighting-clinical-progress-across-its-cd8-targeted-cytokine-pipeline/", "https://asherbio.com/about-us/", "https://asherbio.com/news/in-the-news/", "https://asherbio.com/pipeline/", "https://asherbio.com/wp-content/uploads/2021/05/032921BC_ECP_AsherBio.pdf", "https://forgeglobal.com/asher-biotherapeutics_ipo/", "https://golden.com/wiki/Asher_Biotherapeutics-R9EA884", "https://leadiq.com/c/asher-biotherapeutics/605deb9f5e1d514fc00463d9", "https://startupintros.com/news/2019-08-01-asher-bio-seed", "https://tracxn.com/d/companies/asherbiotherapeutics/__tUfwQphgotV2QUNLcSLWsnQ8rklOetceDiIDV2bq7-I", "https://tracxn.com/d/companies/asherbiotherapeutics/__tUfwQphgotV2QUNLcSLWsnQ8rklOetceDiIDV2bq7-I/funding-and-investors", "https://www.asherbio.com/", "https://www.businesswire.com/news/home/20210323005426/en/Asher-Bio-Launches-with-55-Million-Series-A-Financing-Led-by-Third-Rock-Ventures-to-Discover-and-Develop-Highly-Specific-Immunotherapies-Using-a-Novel-Technology-Platform", "https://www.businesswire.com/news/home/20240416383585/en/Asher-Bio-Closes-55-Million-Series-C-Financing-to-Advance-Lead-Program-into-Phase-1b-Clinical-Trials", "https://www.cbinsights.com/company/asher-bio", "https://www.cbinsights.com/company/asher-bio/financials", "https://www.linkedin.com/company/asher-biotherapeutics", "https://www.linkedin.com/in/crgibbs", "https://www.linkedin.com/in/ivana-djuretic-730a1517/", "https://www.nasdaqprivatemarket.com/company/asher-biotherapeutics/", "https://www.ycombinator.com/companies/asher-bio", "https://yc-oss.github.io/api/batches/summer-2019/asher-bio.json"]